D.Western Therapeutics Institute Inc
TSE:4576
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
D
|
D.Western Therapeutics Institute Inc
TSE:4576
|
JP |
|
V
|
Vaxtex Cotfab Ltd
NSE:VCL
|
IN |
|
C
|
Cokyvina JSC
VN:CKV
|
VN |
|
Panin Financial Tbk PT
IDX:PNLF
|
ID |
|
L
|
Leoni AG
XBER:LEO
|
DE |
|
A
|
Ausquest Ltd
ASX:AQD
|
AU |
|
H
|
Haynes International Inc
F:HYVN
|
US |
|
A
|
Alpha Pro Tech Ltd
AMEX:APT
|
CA |
|
Metalurgica Gerdau SA
BOVESPA:GOAU4
|
BR |
|
A
|
Apogee Optocom Co Ltd
TWSE:6426
|
TW |
|
C
|
Chiu Ting Machinery Co Ltd
TWSE:1539
|
TW |
|
Crown Resorts Ltd
ASX:CWN
|
AU |
|
OSB Group PLC
LSE:OSB
|
UK |
|
A
|
ASP Isotopes Inc
NASDAQ:ASPI
|
US |
|
Thesis Gold Inc
XTSX:TAU
|
CA |
|
V
|
Viet Nam Fumigation JSC
VN:VFG
|
VN |
|
P
|
Privasia Technology Bhd
KLSE:PRIVA
|
MY |
|
Cyberdyne Inc
TSE:7779
|
JP |
D.Western Therapeutics Institute Inc
D. Western Therapeutics Institute, Inc. engages in the research and development of pharmaceutical drugs. The company is headquartered in Nagoya, Aichi-Ken and currently employs 19 full-time employees. The company went IPO on 2009-10-23. The firm generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Company’s drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The firm is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
D. Western Therapeutics Institute, Inc. engages in the research and development of pharmaceutical drugs. The company is headquartered in Nagoya, Aichi-Ken and currently employs 19 full-time employees. The company went IPO on 2009-10-23. The firm generates revenue from licensing of its developed drugs to other companies. As of December 31, 2012, the Company’s drug pipeline included anti-thrombotic medicine K-134, therapeutic agent K-115 for glaucoma, and anticancer drug HMN-214. Its newly-developed products include new anti-thrombotic medicine and signal-transduction inhibitors, including therapeutic agent for high-blood pressure, protective agent for nerves, therapeutic agent for atherosclerosis, ophthalmologic drug and anticancer drug, among others. The firm is also developing new drug candidate compounds focusing on protein kinase inhibitors and involving in ophthalmic surgical adjuvant business, which includes ingredient of Brilliant Blue G-250.
